Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

ute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2006, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promi
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... , March 26, 2015  CNBC profiled MJ Freeway ... part of a series "How I Did It," which features ... the High Road" released yesterday, illustrates how two tech ... leading IT providers to the marijuana industry. ... describes how Co-Founders Amy Poinsett and Jessica Billingsley ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
(Date:3/26/2015)... York (PRWEB) March 26, 2015 ... move forward nationwide, with the issuance of new ... Pennsylvania and Louisiana. According to an Order dated ... litigation established for Xarelto injury claims in the ... now allow plaintiffs to file cases directly in ...
(Date:3/26/2015)... March 26, 2015 “The SWEET Act is ... healthy options more available and help parents who are working ... is a reasonable approach to support public health, and we ... issue for the health of all families,” said Dr. Jane ... Health on the introduction of the Sugar-Sweetened Beverage Tax (SWEET) ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... London, UK (PRWEB) March 26, 2015 In ... 40 billion as of 2013 and is set to decrease ... billion by 2020; the growth is expected up to 2017 ... growth is expected to be owing to the surging penetration ... Tekturna HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... 81-year-old San Francisco woman with dementia, little money and an equally aged ... A 72-year-old Riverside woman with Alzheimer,s who cannot be left safely on ... care for her. A 78-year-old Los Angeles ... take care of him if day care services are cut. ...
... Angeles, London, New Delhi, Singapore and Washington DC (October ... with diabetes to modify their behavior, adjust their medicine ... to a recent study, published by SAGE in ... testing," a self-monitored testing both before and after specific ...
... remains a mystery, , THURSDAY, Oct. 1 (HealthDay News) -- ... still in their mother,s womb were about 20 percent more ... study has found. , The flu outbreak in 1918 killed ... the United States. That flu, like the current H1N1 swine ...
... ... to maximize cell culture media performance and will be on display at BioProcess International ... in Raleigh, North Carolina. , ... Fort Collins, CO (PRWEB) October 1, 2009 -- As conference exhibitor and ...
... The 2nd ... in New York, NY. This three-day conference will explore address all aspects of signal detection ... ... The 2nd DIA Conference on Signal Detection and Data Mining will be held ...
... Support for Addressing Crisis of Chronic Disease , ... are voicing their support for health reform that prioritizes ... to Health Reform" ( www.sayyestohealthreform.com ) - an ... (PFCD) directed at Congressional leaders in Washington. , The campaign ...
Cached Medicine News:Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 2Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 3Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 2Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 3Health News:InVitria's Better Ingredients for Better Media to be Showcased at BPI '09 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 3Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 2Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 3
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: